-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
An -X- _ O
unexpectedly -X- _ O
high -X- _ O
seroprevalence -X- _ O
and -X- _ O
pathogenic -X- _ O
potential -X- _ O
of -X- _ O
human -X- _ B-Patient
parvovirus -X- _ I-Patient
B19 -X- _ I-Patient
( -X- _ I-Patient
B19V -X- _ I-Patient
) -X- _ I-Patient
have -X- _ O
been -X- _ O
observed -X- _ O
in -X- _ O
certain -X- _ O
malaria-endemic -X- _ O
countries -X- _ O
in -X- _ O
parallel -X- _ O
with -X- _ O
local -X- _ O
use -X- _ O
of -X- _ O
chloroquine -X- _ B-Intervention
( -X- _ I-Intervention
CQ -X- _ I-Intervention
) -X- _ I-Intervention
as -X- _ O
first-line -X- _ O
treatment -X- _ O
for -X- _ O
malaria. -X- _ O
The -X- _ O
aims -X- _ O
of -X- _ O
this -X- _ O
study -X- _ O
were -X- _ O
to -X- _ O
assess -X- _ O
the -X- _ O
effect -X- _ O
of -X- _ O
CQ -X- _ B-Intervention
and -X- _ I-Intervention
other -X- _ I-Intervention
common -X- _ I-Intervention
antimalarial -X- _ I-Intervention
drugs -X- _ I-Intervention
on -X- _ O
B19V -X- _ B-Patient
infection -X- _ I-Patient
in -X- _ I-Patient
vitro -X- _ I-Patient
and -X- _ O
the -X- _ O
possible -X- _ O
epidemiological -X- _ O
consequences -X- _ O
for -X- _ O
children -X- _ B-Patient
from -X- _ I-Patient
Papua -X- _ I-Patient
New -X- _ I-Patient
Guinea -X- _ I-Patient
( -X- _ I-Patient
PNG -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
METHODOLOGY -X- _ O
/ -X- _ O
PRINCIPAL -X- _ O
FINDINGS -X- _ O
: -X- _ O
Viral -X- _ O
RNA -X- _ O
, -X- _ O
DNA -X- _ O
and -X- _ O
proteins -X- _ O
were -X- _ O
analyzed -X- _ O
in -X- _ O
different -X- _ O
cell -X- _ O
types -X- _ O
following -X- _ O
infection -X- _ B-Patient
with -X- _ I-Patient
B19V -X- _ I-Patient
in -X- _ O
the -X- _ O
presence -X- _ O
of -X- _ O
a -X- _ O
range -X- _ O
of -X- _ O
antimalarial -X- _ B-Intervention
drugs. -X- _ I-Intervention
Relationships -X- _ O
between -X- _ O
B19V -X- _ B-Patient
infection -X- _ I-Patient
status -X- _ O
, -X- _ O
prior -X- _ O
4-aminoquinoline -X- _ B-Intervention
use -X- _ O
and -X- _ O
anemia -X- _ B-Patient
were -X- _ I-Patient
assessed -X- _ I-Patient
in -X- _ I-Patient
200 -X- _ I-Patient
PNG -X- _ I-Patient
children -X- _ I-Patient
< -X- _ I-Patient
10 -X- _ I-Patient
years -X- _ I-Patient
of -X- _ I-Patient
age -X- _ I-Patient
participating -X- _ O
in -X- _ O
a -X- _ O
case-control -X- _ O
study -X- _ O
of -X- _ O
severe -X- _ O
infections. -X- _ O
In -X- _ B-Outcome
CQ-treated -X- _ I-Outcome
cells -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
synthesis -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
RNA -X- _ I-Outcome
, -X- _ I-Outcome
DNA -X- _ I-Outcome
and -X- _ I-Outcome
proteins -X- _ I-Outcome
was -X- _ I-Outcome
significantly -X- _ I-Outcome
higher -X- _ I-Outcome
and -X- _ I-Outcome
occurred -X- _ I-Outcome
earlier -X- _ I-Outcome
than -X- _ I-Outcome
in -X- _ I-Outcome
control -X- _ I-Outcome
cells. -X- _ I-Outcome
CQ -X- _ I-Outcome
facilitates -X- _ I-Outcome
B19V -X- _ I-Outcome
infection -X- _ I-Outcome
by -X- _ I-Outcome
minimizing -X- _ I-Outcome
intracellular -X- _ I-Outcome
degradation -X- _ I-Outcome
of -X- _ I-Outcome
incoming -X- _ I-Outcome
particles. -X- _ I-Outcome
Only -X- _ I-Outcome
amodiaquine -X- _ I-Outcome
amongst -X- _ I-Outcome
other -X- _ I-Outcome
antimalarial -X- _ I-Outcome
drugs -X- _ I-Outcome
had -X- _ I-Outcome
a -X- _ I-Outcome
similar -X- _ I-Outcome
effect. -X- _ I-Outcome
B19V -X- _ I-Outcome
IgM -X- _ I-Outcome
seropositivity -X- _ I-Outcome
was -X- _ I-Outcome
more -X- _ I-Outcome
frequent -X- _ I-Outcome
in -X- _ I-Outcome
111 -X- _ I-Outcome
children -X- _ I-Outcome
with -X- _ I-Outcome
severe -X- _ I-Outcome
anemia -X- _ I-Outcome
( -X- _ I-Outcome
hemoglobin -X- _ I-Outcome
< -X- _ I-Outcome
50 -X- _ I-Outcome
g -X- _ I-Outcome
/ -X- _ I-Outcome
L -X- _ I-Outcome
) -X- _ I-Outcome
than -X- _ I-Outcome
in -X- _ I-Outcome
89 -X- _ I-Outcome
healthy -X- _ I-Outcome
controls -X- _ I-Outcome
( -X- _ I-Outcome
15.3 -X- _ I-Outcome
% -X- _ I-Outcome
vs -X- _ I-Outcome
3.4 -X- _ I-Outcome
% -X- _ I-Outcome
; -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.008 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
In -X- _ I-Outcome
children -X- _ I-Outcome
who -X- _ I-Outcome
were -X- _ I-Outcome
either -X- _ I-Outcome
B19V -X- _ I-Outcome
IgM -X- _ I-Outcome
or -X- _ I-Outcome
PCR -X- _ I-Outcome
positive -X- _ I-Outcome
, -X- _ I-Outcome
4-aminoquinoline -X- _ I-Outcome
use -X- _ I-Outcome
was -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
significantly -X- _ I-Outcome
lower -X- _ I-Outcome
admission -X- _ I-Outcome
hemoglobin -X- _ I-Outcome
concentration. -X- _ I-Outcome
CONCLUSIONS -X- _ O
/ -X- _ O
SIGNIFICANCE -X- _ O
: -X- _ O
Our -X- _ O
data -X- _ O
strongly -X- _ O
suggest -X- _ O
that -X- _ O
4-aminoquinoline -X- _ B-Intervention
drugs -X- _ I-Intervention
and -X- _ I-Intervention
their -X- _ I-Intervention
metabolites -X- _ I-Intervention
exacerbate -X- _ B-Outcome
B19V- -X- _ B-Patient
associated -X- _ I-Patient
anemia -X- _ I-Patient
by -X- _ O
promoting -X- _ O
B19V -X- _ O
replication. -X- _ O
Consideration -X- _ O
should -X- _ O
be -X- _ O
given -X- _ O
for -X- _ O
choosing -X- _ O
a -X- _ O
non-4-aminoquinoline -X- _ O
drug -X- _ O
to -X- _ O
partner -X- _ O
artemisinin -X- _ O
compounds -X- _ O
in -X- _ O
combination -X- _ O
antimalarial -X- _ O
therapy -X- _ O
. -X- _ O

